Zimmer Biomet

Zimmer Biomet Becomes First and Only Official Medical Device Partner of Association of Pickleball Players, Professional Pickleball Association, and USA Pickleball

Retrieved on: 
Thursday, April 4, 2024
Arthralgia, Health, Organization, USA Pickleball, Importance, Television, Education, Pickleball, Consciousness raising, Naming, Quality of life, Life, Sport, Trusted Partner, Zimmer Biomet, APP, Pain, PPA

WARSAW, Ind., April 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced partnerships with three top pickleball organizations in the United States, becoming the first and only medical device partner for the sport of pickleball. As partners of Zimmer Biomet, the Association of Pickleball Players (APP), Professional Pickleball Association (PPA Tour), and USA Pickleball, the National Governing Body for pickleball, have aligned with the company to alleviate pain and improve the quality of life for the 48.3 million pickleball players1 and millions of spectators across the United States. Of those 48.3 million players, more than half of core players—those who play eight or more times a year—are 55 or older, and almost a third are 65-plus.2

Key Points: 
  • As partners of Zimmer Biomet, the Association of Pickleball Players (APP), Professional Pickleball Association (PPA Tour), and USA Pickleball, the National Governing Body for pickleball, have aligned with the company to alleviate pain and improve the quality of life for the 48.3 million pickleball players1 and millions of spectators across the United States.
  • "Zimmer Biomet is the trusted partner for those who suffer from joint pain.
  • We understand the important role of advanced technology in joint replacement, efficient recovery, and getting back to enjoying life both on and off the court.
  • Pickleball's popularity extends beyond play on the court.

Zimmer Biomet Receives FDA Clearance for ROSA® Shoulder System - the World's First Robotic Assistant for Shoulder Replacement Surgery

Retrieved on: 
Thursday, February 22, 2024
Robotics, Shoulder, MD, FDA, Food, Zimmer Biomet, Surgeon, MBA, ROSA, Orthopedic surgery, Dynamics, Pterygopalatine fossa, Mayo Clinic, Patient, Anatomy, Dentistry

WARSAW, Ind., Feb. 22, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the Company's comprehensive ROSA® Robotics portfolio, which includes the ROSA® Knee System for total knee arthroplasty and ROSA® Hip System for total hip replacement.

Key Points: 
  • WARSAW, Ind., Feb. 22, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery.
  • ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the Company's comprehensive ROSA® Robotics portfolio, which includes the ROSA® Knee System for total knee arthroplasty and ROSA® Hip System for total hip replacement.
  • ROSA Shoulder strengthens Zimmer Biomet's innovative shoulder implant portfolio, which includes the Identity Shoulder System, and joins ZBEdge™ Dynamic Intelligence™ , which has the power to enhance the company's cutting-edge digital technologies, robotics and implant solutions.
  • "We are proud and excited to be the first company in the world to deliver a robotic surgical assistant for anatomic and reverse shoulder replacement surgery," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet.

Zimmer Biomet Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Retrieved on: 
Monday, February 12, 2024
ASC, Shoulder, Zimmer Biomet, Rotation, Surgeon, Standard of care, ROSA, Fatigue, Outpatient surgery, Knee, Robotics, AAOS, Tibia, American Academy

WARSAW, Ind., Feb. 12, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is showcasing the latest innovations across its product portfolio at the 2024 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) this week in San Francisco. During the meeting, the company will display its forthcoming ROSA® Robotics application for shoulder replacement,* which is pending 510(k) clearance, and provide hands-on demonstrations of key growth drivers including Persona® OsseoTi® Keel Tibia for cementless knee replacement, ROSA® Robotics (ROSA Knee and ROSA Hip), Ambulatory Surgery Center (ASC) Solutions, as well as recently launched surgical tools including HAMMR™ Automatic Hip Impaction System, and the ViVi® Surgical Helmet System.

Key Points: 
  • "Every year, the annual AAOS meeting gives us an opportunity to not only demonstrate the breadth and diversity of our portfolio, but also shine a spotlight on the bold and meaningful innovations that transform clinical care, improve the surgical experience, and give us a differentiated competitive advantage," said Mark Bezjak, President of the Americas at Zimmer Biomet.
  • ZBEdge™ Dynamic Intelligence™ : Elevates and unlocks the full potential of Zimmer Biomet's cutting-edge digital, robotic and implant solutions.
  • In addition, the company will provide updates on its ASC strategy, partnerships and comprehensive portfolio.
  • For more information about Zimmer Biomet events at AAOS 2024, visit http://www.zimmerbiomet.com/academy2024 .

ABANZA Strengthens US Operations with Established Orthopedic Industry Expert, John Rizzo, as Executive Vice President

Retrieved on: 
Monday, January 22, 2024
Senior, Acquisition, Executive, Soft tissue, Zimmer Biomet, Growth, Management

NAVARRA, Spain, Jan. 22, 2024 /PRNewswire/ -- ABANZA is excited and honored to announce the strategic addition of Executive Vice President for US operations, JOHN RIZZO.

Key Points: 
  • NAVARRA, Spain, Jan. 22, 2024 /PRNewswire/ -- ABANZA is excited and honored to announce the strategic addition of Executive Vice President for US operations, JOHN RIZZO.
  • With a distinguished career spanning over three decades in the orthopedic medical device industry, John Rizzo brings a wealth of experience in building successful teams and distribution channels, both in start-up ventures and mature growth scenarios.
  • Prior to joining ABANZA, Rizzo served as the Senior Vice President of Sales at Embody Inc., playing a pivotal role in the company's transformation from pre-revenue to a successful acquisition by Zimmer Biomet in February 2023.
  • As ABANZA welcomes John Rizzo to its leadership team, the company is gearing up for an exciting phase of growth in the US market.

Plug and Play Opens New Medtech Office in Warsaw, Indiana

Retrieved on: 
Wednesday, January 17, 2024
Paragon, University, NEI, SDC, City, Commerce, Orthopedic surgery, Business development, Entrepreneurship, Zimmer Biomet, Medtech, Workforce, Organization, AMETEK, Plug and play, Growth, Renewable energy

The new office will be located in the heart of Warsaw, Indiana, renowned for its thriving medtech ecosystem.

Key Points: 
  • The new office will be located in the heart of Warsaw, Indiana, renowned for its thriving medtech ecosystem.
  • Plug and Play aims to leverage the regional expertise and resources to drive collaboration and accelerate the growth of startups in the medtech sector.
  • Plug and Play's expansion into Warsaw, Indiana supports the vision of Zimmer Biomet to transform Warsaw from the Orthopedic capital to the medtech capital of the world.
  • Brandon Noll, former Vice President of Business Development for NEI, has recently joined Plug and Play as the Director of Indiana.

Industry Leader Greg Roche Joins Distalmotion as CEO

Retrieved on: 
Thursday, December 7, 2023
Roche, Medtech, Zimmer Biomet, Robotics, 3D printing

Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.

Key Points: 
  • Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.
  • Roche joins Distalmotion with more than 20 years of commercial and executive experience in the Medtech industry, bringing a wealth of expertise across laparoscopic surgery, endoscopic visualization, and surgical robotics.
  • Most recently, Roche served as CEO of avateramedical, adding to his leadership and experience within soft-tissue robotic technologies.
  • “I am thrilled to join Distalmotion – we have an incredible and talented team that has positioned Distalmotion to become a leader in the next generation of surgical robotics.

Industry Leader Greg Roche Joins Distalmotion as CEO

Retrieved on: 
Thursday, December 7, 2023
Roche, Medtech, Zimmer Biomet, Robotics, 3D printing

Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.

Key Points: 
  • Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.
  • Roche joins Distalmotion with more than 20 years of commercial and executive experience in the Medtech industry, bringing a wealth of expertise across laparoscopic surgery, endoscopic visualization, and surgical robotics.
  • Most recently, Roche served as CEO of avateramedical, adding to his leadership and experience within soft-tissue robotic technologies.
  • “I am thrilled to join Distalmotion – we have an incredible and talented team that has positioned Distalmotion to become a leader in the next generation of surgical robotics.

Zimmer Biomet to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 19, 2023
Conference, Zimmer Biomet

WARSAW, Ind., Dec. 19, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:15 a.m. PT (11:15 a.m.

Key Points: 
  • WARSAW, Ind., Dec. 19, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:15 a.m. PT (11:15 a.m.
  • ET).
  • A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com .
  • The webcast will be archived for replay following the conference.

3D BioFibR Appoints Dr. Michael Francis as Independent Board Member

Retrieved on: 
Monday, December 4, 2023
Technology, Textiles, Engineering, Genetics, Nanotechnology, Manufacturing, Biotechnology, Health, Pharmaceutical, Research, AFWERX, Zimmer Biomet, DARPA, Regenerative medicine, Tissue engineering, Army, NIH, 3D printing

3D BioFibR Inc. (“3D BioFibR”), a leading innovator in the field of tissue engineering and regenerative medicine, today announced that it has appointed Michael Francis, Ph.D., to its Board of Directors.

Key Points: 
  • 3D BioFibR Inc. (“3D BioFibR”), a leading innovator in the field of tissue engineering and regenerative medicine, today announced that it has appointed Michael Francis, Ph.D., to its Board of Directors.
  • Dr. Francis brings a wealth of experience in research and development and partnering of novel products using advanced collagen fiber manufacturing technologies.
  • Kevin Sullivan, CEO of 3D BioFibR said, “We are pleased to welcome Michael to 3D BioFibR’s Board.
  • “3D BioFibR is advancing a completely novel way of manufacturing collagen fibers for the tissue engineering and regenerative medicine market,” said Dr. Francis.

Orthopedic 3D printed devices market size to grow by USD 1.35 billion from 2023 to 2028 | North America to account for 40% of market growth- Technavio

Retrieved on: 
Thursday, December 14, 2023
EOS, Plastic, ROW, Renishaw plc, SLM Solutions Group AG, Research, 3D Systems, USD, Zimmer Biomet, Medtronic, Biomaterial, Instrument, Geography, Growth, 3D, Smith, Device, Medical device, Retail, 3D printing

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The orthopedic 3D printed devices market size is expected to grow by USD 1.35 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The orthopedic 3D printed devices market size is expected to grow by USD 1.35 billion from 2023 to 2028.
  • Orthopedic 3D Printed Devices Market: Segmentation Analysis
    The orthopedic implants segment is estimated to witness significant growth during the forecast period.
  • Detailed information on factors that will drive the growth of the orthopedic 3D printed devices market between 2023 and 2028.
  • Growth of the market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of orthopedic 3D printed devices market companies.